Inflammatory myofibroblastic tumor
MONDO:0015798A multinodular intermediate fibroblastic neoplasm that arises from soft tissue or viscera, in children and young adults. It is characterized by the presence of spindle-shaped fibroblasts and myofibroblasts, and a chronic inflammatory infiltrate composed of eosinophils, lymphocytes, and plasma cells.
Also known as: IMT, inflammatory fibrosarcoma, inflammatory myofibroblastic neoplasm, inflammatory myofibroblastic tumor, inflammatory pseudotumor
1450 clinical trials for this condition and its sub-types, 8 tagged with Inflammatory myofibroblastic tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Inflammatory myofibroblastic tumor
-
Pfizer offers lifeline: ongoing crizotinib access for cancer patients
Disease control OngoingThis study allows people with certain cancers (NSCLC, ALCL, IMT) who are already benefiting from crizotinib in a previous Pfizer study to keep receiving the drug after that study ends. About 27 participants will continue treatment while doctors monitor for side effects. The goal …
Phase 4 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Last-Resort access to ceritinib for ALK-Positive cancer patients
Disease control Expanded access (ended)This program provides access to the drug ceritinib (LDK378) for patients with serious ALK-positive tumors, including non-small cell lung cancer, who have no other treatment options and cannot join a clinical trial. It is designed for individual patients whose doctors request the …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC